News
Bavencio + axitinib combination accepted for use within NHS Scotland for the first-line treatment of adult patients with advanced renal cell carcinoma. Merck KGaA + Pfizer
Merck KGaA and Pfizer’s immunotherapy Bavencio (avelumab) combined with axitinib is accepted for use within NHS Scotland for the first-line treatment of adult patients with advanced Renal Cell Carcinoma (aRCC). Previously available as part of the Early Access to Medicines Scheme (EAMS) and recently approved by NICE, this combination will provide a new first line treatment option for patients from all prognostic groups, filling a huge unmet need in this area. Results from the JAVELIN Renal 101 study comparing Bavencio® (avelumab) plus axitinib with sunitinib demonstrated that this combination:• Significantly lowered risk of disease progression or death by 31% across all prognostic risk groups. • Nearly doubled objective response rate (52.5% vs. 27.3%).
Condition: Renal Cell Carcinoma
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins